BioAtla, Inc. SEC filings BCAB
BioAtla, Inc. has 509 filings in SEC EDGAR's recent list, going back to Oct 6, 2020. Its latest annual report, Form ARS, was filed on Jun 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (material agreement, agreement ended, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 29, 2026 | — |
| 424B3 | Prospectus | Oct 29, 2026 | — |
| RW | Filing | Oct 27, 2026 | — |
| S-1 | Registration statement | Oct 20, 2026 | — |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale
|
Oct 20, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 28, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 16, 2026 | Jul 16, 2026 |
| ARS | Annual report to shareholders | Jun 3, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Jun 3, 2026 | — |
| DEF 14A | Proxy statement | Jun 3, 2026 | Jun 3, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 29, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Other events
|
Apr 2, 2026 | Apr 2, 2026 |
| S-8 | Employee stock plan registration | Mar 31, 2026 | — |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Mar 23, 2026 | Mar 17, 2026 |
| 424B2 | Prospectus | Mar 20, 2026 | — |
| 424B2 | Prospectus | Mar 13, 2026 | — |
| 424B2 | Prospectus | Mar 9, 2026 | — |
| DEFA14A | Additional proxy material | Mar 2, 2026 | — |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change, Regulation FD disclosure, Other events
|
Mar 2, 2026 | Feb 24, 2026 |
| DEFM14A | Filing | Feb 11, 2026 | — |
| 8-K |
Current report
Other events
|
Feb 9, 2026 | Feb 8, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Feb 6, 2026 | Feb 6, 2026 |
| PREM14A | Filing | Jan 30, 2026 | Jan 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure, Other events
|
Jan 30, 2026 | Jan 26, 2026 |
| S-3 | Shelf registration | Jan 16, 2026 | — |
| DEFA14A | Additional proxy material | Jan 15, 2026 | — |
| 8-K |
Current report
Unregistered share sale, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Jan 12, 2026 | Jan 9, 2026 |
| DEFA14A | Additional proxy material | Dec 31, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 31, 2025 | Dec 30, 2025 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Dec 30, 2025 | Dec 30, 2025 |
| DEF 14A | Proxy statement | Dec 5, 2025 | Dec 5, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 24, 2025 | Nov 24, 2025 |
| 424B5 | Prospectus supplement | Nov 21, 2025 | — |
| 8-K |
Current report
Material agreement, New debt
|
Nov 21, 2025 | Nov 20, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Other events
|
Sep 22, 2025 | Sep 16, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 20, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Listing notice
|
May 16, 2025 | May 12, 2025 |
| 424B3 | Prospectus | May 16, 2025 | — |
| EFFECT | Filing | May 14, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| UPLOAD | Letter from the SEC | May 9, 2025 | — |
| S-3 | Shelf registration | May 6, 2025 | — |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| ARS | Annual report to shareholders | Apr 24, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Apr 24, 2025 |
| S-8 | Employee stock plan registration | Mar 28, 2025 | — |
| 10-K | Annual report | Mar 28, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 14, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Listing notice
|
Feb 7, 2025 | Feb 6, 2025 |
| 424B5 | Prospectus supplement | Dec 20, 2024 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 20, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 20, 2024 | Dec 20, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 23, 2024 | Sep 23, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Other events
|
May 17, 2024 | May 15, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 24, 2024 | Apr 22, 2024 |
| ARS | Annual report to shareholders | Apr 24, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 24, 2024 | Jun 13, 2024 |
| S-8 | Employee stock plan registration | Mar 26, 2024 | — |
| 10-K | Annual report | Mar 26, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2024 | Mar 26, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 21, 2024 | Feb 15, 2024 |
| 8-K |
Current report
Other events
|
Feb 12, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2024 | Jan 9, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jan 8, 2024 | Jan 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 13, 2023 | Dec 13, 2023 |
| 8-K |
Current report
Other events
|
Dec 4, 2023 | Dec 4, 2023 |
| 10-Q | Quarterly report | Nov 7, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 10-Q | Quarterly report | Aug 1, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 1, 2023 | Aug 1, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2023 | Jun 14, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| DEFA14A | Additional proxy material | Apr 24, 2023 | — |
| ARS | Annual report to shareholders | Apr 24, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Apr 24, 2023 | Jun 14, 2023 |
| S-8 | Employee stock plan registration | Mar 23, 2023 | — |
| 10-K | Annual report | Mar 23, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2023 | Mar 23, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 27, 2023 | Feb 24, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 15, 2023 | Feb 9, 2023 |
| EFFECT | Filing | Jan 17, 2023 | — |
| CORRESP | Letter to the SEC | Jan 13, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 13, 2023 | — |
| S-3 | Shelf registration | Jan 6, 2023 | — |
| 8-K |
Current report
Material agreement
|
Jan 6, 2023 | Jan 6, 2023 |
| 424B5 | Prospectus supplement | Jan 6, 2023 | — |
| 8-K |
Current report
Material agreement
|
Nov 7, 2022 | Nov 4, 2022 |
| 424B5 | Prospectus supplement | Nov 7, 2022 | — |
| 8-K |
Current report
Other events
|
Nov 4, 2022 | Nov 4, 2022 |
| 10-Q | Quarterly report | Nov 4, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| 8-K |
Current report
Officer or director change
|
Sep 21, 2022 | Sep 15, 2022 |
| 10-Q | Quarterly report | Aug 9, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2022 | Jun 16, 2022 |
| 8-K |
Current report
Officer or director change
|
Jun 6, 2022 | Jun 3, 2022 |
| EFFECT | Filing | May 18, 2022 | — |
| POS AM | Filing | May 17, 2022 | — |
| 10-Q | Quarterly report | May 5, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 4, 2022 | May 4, 2022 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 16, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 11, 2022 | Apr 11, 2022 |
| 424B3 | Prospectus | Mar 1, 2022 | — |
| S-8 | Employee stock plan registration | Mar 1, 2022 | — |
| POS AM | Filing | Mar 1, 2022 | — |
| 10-K | Annual report | Feb 28, 2022 | Dec 31, 2021 |
| POSASR | Filing | Feb 28, 2022 | — |
| 8-K |
Current report
Officer or director change
|
Feb 25, 2022 | Feb 21, 2022 |
| S-3ASR | Automatic shelf registration | Feb 4, 2022 | — |
| 8-K |
Current report
Material agreement
|
Jan 11, 2022 | Jan 5, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 21, 2021 | Dec 16, 2021 |
| 8-K |
Current report
Agreement ended
|
Nov 19, 2021 | Nov 18, 2021 |
| 10-Q | Quarterly report | Nov 15, 2021 | Sep 30, 2021 |
| EFFECT | Filing | Nov 3, 2021 | — |
| 424B3 | Prospectus | Nov 3, 2021 | — |
| CORRESP | Letter to the SEC | Nov 1, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 29, 2021 | — |
| S-1 | Registration statement | Oct 22, 2021 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 29, 2021 | Sep 28, 2021 |
| 10-Q | Quarterly report | Aug 13, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2021 | Jun 15, 2021 |
| 10-Q | Quarterly report | May 12, 2021 | Mar 31, 2021 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 15, 2021 |
| S-8 | Employee stock plan registration | Mar 24, 2021 | — |
| 10-K | Annual report | Mar 24, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Officer or director change
|
Feb 9, 2021 | Feb 3, 2021 |
| S-8 | Employee stock plan registration | Dec 18, 2020 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 18, 2020 | Dec 18, 2020 |
| 424B4 | Prospectus | Dec 17, 2020 | — |
| EFFECT | Filing | Dec 15, 2020 | — |
| S-1MEF | Filing | Dec 15, 2020 | — |
| CERT | Filing | Dec 14, 2020 | — |
| CORRESP | Letter to the SEC | Dec 11, 2020 | — |
| CORRESP | Letter to the SEC | Dec 11, 2020 | — |
| SEC STAFF LETTER | Filing | Dec 10, 2020 | — |
| 8-A12B | Filing | Dec 9, 2020 | — |
| CORRESP | Letter to the SEC | Dec 9, 2020 | — |
| S-1/A | Amended registration statement | Dec 9, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 8, 2020 | — |
| CORRESP | Letter to the SEC | Dec 8, 2020 | — |
| S-1/A | Amended registration statement | Dec 8, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2020 | — |
| SEC STAFF LETTER | Filing | Nov 23, 2020 | — |
| CORRESP | Letter to the SEC | Nov 13, 2020 | — |
| S-1 | Registration statement | Nov 13, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 4, 2020 | — |
| DRS | Filing | Oct 6, 2020 | — |
Showing 171 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCAB (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1826892
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.